Who
Antonio S. Montecalvo
Vice President, Health Policy
Company insider
Files Form 4 as: Vice President, Health Policy, Organogenesis Holdings.
In numbers
- Trades disclosed
- 58
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $903K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 10 Dec 2018
- Last trade
- 18 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —11,330 at $0.00 | filing |
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $15K3,778 at $3.84 | filing |
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —11,330 at $0.00 | filing |
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $15K3,778 at $3.84 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —40,625 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —11,218 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $14K3,741 at $3.84 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,162 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,162 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —40,625 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —11,218 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $14K3,741 at $3.84 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $5,1811,389 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $36K9,607 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $15K4,100 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $13K3,523 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $5,1811,389 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $36K9,607 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $15K4,100 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $13K3,523 at $3.73 | filing |
News
Organogenesis (NASDAQ:ORGO) Shares Down 3.6% – What's Next?ORGO · tickerreport.com · 24 Oct 2026
0 headlines in the last 90 days name Antonio S. Montecalvo; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.